Literature DB >> 35622247

δ2-Opioid Receptors as a Target in Designing New Cardioprotective Drugs: the Role of Protein Kinase C, AMPK, and Sarcolemmal KATP Channels.

A V Mukhomedzyanov1, S V Popov2, L N Maslov2.   

Abstract

In rats anesthetized with α-chloralose, coronary artery occlusion (45 min) and reperfusion (120 min) were modeled. The selective δ2-opioid receptor agonist deltorphin II was administered 5 min before reperfusion. Protein kinase C inhibitor chelerythrine, AMP-activated protein kinase inhibitor compound C, and ATP-sensitive K+ channel blockers glibenclamide, 5-hydroxydecanoate, and HMR 1098 were administered 10 min before reperfusion. It was found that the infarct-limiting effect of deltorphin II is associated with activation of protein kinase C and opening of sarcolemmal ATP-sensitive K+ channel.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  AMPK; KATP channels; ischemia/reperfusion; opioid receptors; protein kinase C

Mesh:

Substances:

Year:  2022        PMID: 35622247     DOI: 10.1007/s10517-022-05487-2

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  13 in total

1.  Door-to-balloon time and mortality among patients undergoing primary PCI.

Authors:  Daniel S Menees; Eric D Peterson; Yongfei Wang; Jeptha P Curtis; John C Messenger; John S Rumsfeld; Hitinder S Gurm
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

2.  Ischemic preconditioning in rats: role of mitochondrial K(ATP) channel in preservation of mitochondrial function.

Authors:  R M Fryer; J T Eells; A K Hsu; M M Henry; G J Gross
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-01       Impact factor: 4.733

3.  Cardioprotective effect of chronic hypoxia is blunted by concomitant hypercapnia.

Authors:  J Neckár; O Sźárszoi; J Herget; B Ostádal; F Kolár
Journal:  Physiol Res       Date:  2003       Impact factor: 1.881

4.  Opioid-induced cardioprotection against myocardial infarction and arrhythmias: mitochondrial versus sarcolemmal ATP-sensitive potassium channels.

Authors:  R M Fryer; A K Hsu; H Nagase; G J Gross
Journal:  J Pharmacol Exp Ther       Date:  2000-08       Impact factor: 4.030

5.  Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention.

Authors:  Ivan Olier; Alex Sirker; David J R Hildick-Smith; Tim Kinnaird; Peter Ludman; Mark A de Belder; Andreas Baumbach; Jonathan Byrne; Muhammad Rashid; Nick Curzen; Mamas A Mamas
Journal:  Heart       Date:  2018-02-02       Impact factor: 5.994

6.  Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury.

Authors:  Kasem Nithipatikom; Jeannine M Moore; Marilyn A Isbell; John R Falck; Garrett J Gross
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-02-10       Impact factor: 4.733

7.  Activation of peripheral delta2 opioid receptors increases cardiac tolerance to ischemia/reperfusion injury Involvement of protein kinase C, NO-synthase, KATP channels and the autonomic nervous system.

Authors:  Leonid N Maslov; Yury B Lishmanov; Peter R Oeltgen; Eva I Barzakh; Andrey V Krylatov; Meera Govindaswami; Stephen A Brown
Journal:  Life Sci       Date:  2009-02-24       Impact factor: 5.037

Review 8.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

9.  Redefining successful primary PCI.

Authors:  Peter J McCartney; Colin Berry
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2019-02-01       Impact factor: 6.875

10.  Comparative Analysis of Infarct Size Limiting Activity of δ-Opioid Receptor Agonists in Reperfused Heart In Vivo.

Authors:  A V Mukhomedzyanov; S Yu Tsibulnikov; A V Krylatov; L N Maslov
Journal:  Bull Exp Biol Med       Date:  2021-04-01       Impact factor: 0.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.